Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy (Q34585191)

3 August 2017

1 reference

title

Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy (English)

1 reference

3 August 2017

0 references

Alexandros A Drosos

1

1 reference

3 August 2017

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

62

1 reference

3 August 2017

6

1 reference

3 August 2017

891-907

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262060-00003

3 August 2017

0 references

cites work

Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthr

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study

1 reference

12 December 2020

The inhibition of nucleic acid synthesis by mycophenolic acid

1 reference

12 December 2020

Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene

1 reference

12 December 2020

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).

1 reference

12 December 2020

Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients

1 reference

12 December 2020

p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

1 reference

12 December 2020

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

12 December 2020

p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials

1 reference

12 December 2020

Cyclosporin A and FK-506 inhibit development of superantigen-potentiated collagen-induced arthritis in mice

1 reference

12 December 2020

Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase

1 reference

12 December 2020

Immunosuppressive effect of FK506 on collagen-induced arthritis in rats

1 reference

12 December 2020

Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.

1 reference

12 December 2020

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

1 reference

12 December 2020

FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells

1 reference

12 December 2020

Rheumatoid arthritis. Pathophysiology and implications for therapy

1 reference

12 December 2020

RS-61443--a new, potent immunosuppressive agent

1 reference

12 December 2020

The effects of interleukin-1 receptor antagonist on oxidant-induced arthritis in mice.

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

Potent inhibitors of the MAP kinase p38

1 reference

12 December 2020

Jun N-terminal kinase in rheumatoid arthritis.

1 reference

12 December 2020

FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis

1 reference

12 December 2020

The immunopathogenesis of rheumatoid arthritis

1 reference

12 December 2020

Mitogen-activated protein kinase cascades and regulation of gene expression

1 reference

12 December 2020

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Inhibition of the immune response by rapamycin, a new antifungal antibiotic

1 reference

12 December 2020

How does leflunomide modulate the immune response in rheumatoid arthritis?

1 reference

12 December 2020

Cyclosporine in rheumatoid arthritis

1 reference

12 December 2020

Tacrolimus, a new immunosuppressant--a review of the literature

1 reference

12 December 2020

Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

1 reference

12 December 2020

Inhibition of T and B lymphocyte proliferation by rapamycin

1 reference

12 December 2020

Biologic basis for interleukin-1 in disease

1 reference

12 December 2020

Studies in the biochemistry of micro-organisms. 86. The molecular constitution of mycophenolic acid, a metabolic product of Penicillium Brevi-compactum Dierckx. Part III. Further observations on the structural formula for mycophenolic acid

1 reference

12 December 2020

Investigational agents for rheumatoid arthritis

1 reference

12 December 2020

The immunopathogenesis of rheumatoid arthritis

1 reference

12 December 2020

The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review

1 reference

12 December 2020

The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase

1 reference

12 December 2020

Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

1 reference

12 December 2020

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

12 December 2020

Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group

1 reference

12 December 2020

Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice

1 reference

12 December 2020

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1

1 reference

12 December 2020

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

12 December 2020

Metabolism and biochemistry of mycophenolic acid

1 reference

12 December 2020

Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study

1 reference

12 December 2020

Mechanism of action for leflunomide in rheumatoid arthritis

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

New insights into the pathogenesis and treatment of rheumatoid arthritis

1 reference

12 December 2020

Rapamycin, a potential disease-modifying antiarthritic drug

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

12 December 2020

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

1 reference

12 December 2020

Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold

1 reference

12 December 2020

Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

12 December 2020

Intracellular signaling pathways as a target for the treatment of rheumatoid arthritis

1 reference

12 December 2020

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

1 reference

12 December 2020

The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter

1 reference

12 December 2020

Signal transduction and transcription factors in rheumatic disease

1 reference

12 December 2020

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

12 December 2020

Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus

1 reference

12 December 2020

Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells

1 reference

12 December 2020

Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action

1 reference

12 December 2020

The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts

1 reference

12 December 2020

Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study

1 reference

12 December 2020

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.

1 reference

12 December 2020

IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase

1 reference

12 December 2020

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

1 reference

12 December 2020

A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis

1 reference

12 December 2020

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

12 December 2020

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a

1 reference

12 December 2020

Discovery of a new class of p38 kinase inhibitors

1 reference

12 December 2020

Transcription factor ATF2 regulation by the JNK signal transduction pathway

1 reference

12 December 2020

Molecular medicine. Transcription factors

1 reference

12 December 2020

The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation

1 reference

12 December 2020

SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes.

1 reference

12 December 2020

Cyclosporine, FK-506, rapamycin, and other immunomodulators

1 reference

12 December 2020

Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms

1 reference

12 December 2020

Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059

1 reference

12 December 2020

Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways.

1 reference

12 December 2020

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

1 reference

12 December 2020

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin

1 reference

12 December 2020

Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models

1 reference

12 December 2020

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

12 December 2020

10.2165/00003495-200262060-00003

Identifiers

DOI

1 reference

PubMed ID

11929337

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

11929337